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Introduction {#s1}
============

Bisphosphonates (BPs) are inorganic pyrophosphate analogs that accumulate on the bone surface and inhibit bone resorption by osteoclast apoptosis. They are used extensively for managing the osteoporosis with considerable clinical benefits in the reduction of fragility fractures. However, rare associations of subtrochanteric atypical femoral fractures have been reported post marketing, often after long term BP therapy ([@R1]-[@R4]).

Atypical fractures of femoral shaft or subtrochanteric area were accounted for \<0.1% of total fracture admissions ([@R5]) and are strongly associated with BPs but they are rather uncommon ([@R6]).These fractures occur after a low energy trauma and they have a typical simple transverse or oblique radiographic pattern, with focal or generalized increase in cortical thickness, cortical beaking, and medial spiking and they may be bilateral ([@R2],[@R7],[@R8]). Lower age, probably due to the high physical activity, unknown genetic factors, thicker cortex and long duration of BP use, suboptimal 25-OHD level, and bone density in the non-osteoporotic range might play important roles ([@R6],[@R9]). It is suggested that the pathogenesis of these fractures are related to the profound osteoclast inhibition and the resulting suppression of the bone turnover and bone remodeling ([@R10],[@R11]).

Long term use of BPs may cause insufficiency fractures due to the depressed bone remodeling, reduction of mechanical properties under cyclic loading conditions and oversuppression of bone turnover leading to microdamages and reduced bone strength ([@R3],[@R12],[@R13]).

In some case reports and series, the patients\' ages differed from 46 to 76 years ([@R3],[@R4]) and the duration of BP usage varied from 3 to 16 years ([@R4],[@R13],[@R14]). Other studies evaluated older osteoporotic patients ([@R10]) with long term alendronate more than 5 years ([@R3],[@R10]) but there are some reports in which atypical fractures happened earlier than 5 years ([@R4],[@R14],[@R15]). The comparison between BMD scan and pelvic X-ray has not been done either ([@R10]).

A large number of patients receive long term BP treatment, therefore, recognition of the side effects, especially atypical fractures are very important. In this study, we compared osteopenic/osteoporotic postmenopausal women in two groups according to receiving alendronate for femoral cortical thickness in BMD and plain pelvic Xray as a predictor for atypical fracture.

Methods {#s2}
=======

In this historical cohort study, 49 osteopenic or osteoporotic out patients who were treated by alendronate for at least one year were compared to 49 controls for cortical thickness in subthrochantric and proximal portion of femur in a rheumatology clinic in Mazandaran, north of Iran, in 2013- 14. The sample size based on random sampling method was calculated according to results of Unnanuntana study for mean and SD of CT in cases and controls ([@R10]), with power and confidence level of 90% and 95%, respectively. Approval was obtained from the Ethics Committee of Mazandaran University of Medical Sciences.

All participants were post-menopausal women aged 50-70 years, diagnosed with osteopenia or osteoporosis according to bone mineral densitometry (BMD) (by lunar prodigy, USA, GE Company). Osteopenia and osteoporosis were defined as T-Score between -1to -2.5 and T-Score\< -2.5, respectively.

Patients who were treated with other BPs (other than alendronate) or raloxifen, became menopause before 45 years of age , those with hyperthyroidism, hyperparathyroidism, inflammatory rheumatologic disorders such as rheumatoid arthritis, inflammatory bowel diseases, glucocorticoid using, and cigarette smoking were excluded from the study. Patients with body mass index (BMI) lower than 18.5 or higher than 30 were also excluded. Controls were postmenopausal women meeting similar criteria but without history of alendronate consumption. Data collected for each patient included demographic information and osteoporosis related data. Cortical thickness in subtrochanteric area and proximal of femural shaft were measured in 3.5 and 4 cm of greater trochanter (GT) and 0.5 cm under smaller trochanter (LT) in BMD and in 9.5 and 10.5 cm of GT and 1 cm under LT in plain pelvic graphs (Shimadsu, Japan) according to accommodation of size in this Xray of a patient.

Diameter of femur, cortical thickness, medullary canal diameter and cortical thickness ratio was measured in these regions ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).
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Statistical analysis was performed by t-test and Chi square tests for comparing quantitative and qualitative variables in two groups, respectively. Descriptive statistics were performed to determine the changes in cortical thickness and percent change in cortical thickness using SPSS version 20. p\<0.05 was considered significant.

Results {#s3}
=======

In this historical cohort study 98 osteopenic/osteoporotic post-menopausal women were compared in two groups (n=49 patients per group) for femoral cortical thickness according to alendronate usage. Their mean±SD age and age at menopause was 60.2±5.60 and 49.4± 2.70 years, respectively. Duration of BP consumption in alendronate group was 1.76±1.38 ([@R1]-[@R10]) years. Patients were considered osteopenic and osteoporotic if their T-Score was 42 (42.85%) and 46 (46.9%) in lumbar spine and 47(47.95%) and 6(6.1%) in hip. There were no significant differences between the two groups in demographic and baseline data parameters in osteopenic or osteoporotic patients except for calcium supplementation in alendronate group (p\<0.05).

Demographic and baseline data of patients and some OP related charachteristics are shown in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

###### Demographic and baseline characteristics of participants.

  ---------------------------------- ------------------- ------------- ------
  Variables                          Alendronate group   Controls      p
  Age                                61.06±5.3           59.3±5.8      0.12
  BMI                                26.45± 2.8          26.2± 2.7     0.61
  Age at menopause                   49.0±2.6            49.81±2.8     0.13
  Walking (h/day)                    2.52±2.9            2.50±2.6      1
  History of calcium using (years)   2.33± 3.3           0.52±0.7      0.00
  Serum calcium (mg/dl)              9.13±0.5            9.01±0.3      0.09
  Alkaline phosphotase (u/l)         208.40±44.9         215.92±38.8   0.38
  Level of 25 OH D (ng/ml)           31.04±9.3           30.22±10.9    0.69
  Serum creatinine(mg/dl)            0.81±0.1            0.87±0.2      0.08
  BMD in hip (g/cm2)                 0.86±0.1            0.86±0.1      0.78
  T score in hip                     -1.16±0.9           -1.08± 0.9    0.68
  BMD in spine                       0.89± 0.1           0.92± 0.1     0.32
  T score in spine(g/cm2)            -2.40± 1            -2.15± 1      0.23
  ---------------------------------- ------------------- ------------- ------

###### Some osteoporosis related characteristics of participants.

  -------------------------------------------- ------------------- ----------- ------
  Variables                                    Alendronate group   Controls    p
  History of fragility fracture (N,%)          3 (6.1%)            4 (6.8%)    0.70
  Family history of fragility fracture (N,%)   7 (12.9%)           3 (6.1%)    0.20
  Thigh pain (N,%)                             2 (3.4%)            4 (6.8%)    0.40
  Proton pump inhibitor user (N,%)             4 (6.8%)            5 (10.2%)   0.73
  -------------------------------------------- ------------------- ----------- ------

We observed no differences in mean of cortical thickness and cortical thickness ratio between the alendronate and control groups neither in BMD scan nor in X-ray (p\<0.05).

The cortical thickness parameters in DXA pelvic X-ray are demonstrated in [Table 3](#T3){ref-type="table"}. Results of measurements in 4 cm of GT in DXA and 10.5 cm in X-ray were similar to 3.5 and 9.5 cm, respectively, which are not listed in the table. Correlations of these results between X-ray and densitometry are shown in [Table 4](#T4){ref-type="table"}.

###### DXA scan and plain measurements of femoral cortex

  --------------------------------- ------------------- ------------- ------
  Measurement                       Alendronate group   Controls      p

  3.5 cm below GT (DXA)                                               

  Femoral shaft diameter (mm)       12.45±0.9           12.37± 0.9    0.64

  Medullary canal diameter (mm)     5.98± 0.9           6.02±0.9      0.86

  Cortical thickness (mm)           6.46± 0.7           6.35± 0.8     0.47

  Cortical thickness ratio (%)      52.02± 5.6          51.34± 6.08   0.56

  0.5 cm below LT (DXA)                                               

  Femoral shaft diameter (mm)       12.86±0.8           12.68± 0.8    0.29

  Medullary canal diameter (mm)     6.90±0.9            6.91± 0.9     0.96

  Cortical thickness (mm)           5.96±0.57           5.76± 0.52    0.07

  Cortical thickness ratio (%)      46.50±5.0           45.55± 4.5    0.32

  9.5 cm below GT (in plane Xray)                                     

  Femoral shaft diameter (mm)       33.08± 3.2          33.52± 2.8    0.47

  Medullary canal diameter (mm)     19.64± 3.3          19.47± 2.9    0.79

  Cortical thickness (mm)           13.41± 2.3          14.04± 1.8    0.14

  Cortical thickness ratio (%)      40.70± 6.6          42.03± 5.42   0.27

  1 cm below LT (in plane X ray)                                      

  Femoral shaft\                    \                   \             \
  diameter (mm)                     34.08± 3.1          34.51± 2.71   0.47

  Medullary canal diameter (mm)     21.8± 3.1           22.06± 3.1    0.69

  Cortical thickness (mm)           12.27± 1.7          12.44± 1.8    0.63

  Cortical thickness ratio (%)      36.19± 5.2          36.18± 5.7    0.99
  --------------------------------- ------------------- ------------- ------

###### Correlation of DXA and plain measurements of femoral cortex

  ------------------------------------------------------------------- ------------- ---------
  Region                                                              Correlation   p
  Cortical thickness: 3.5 cm (DXA) and 9.5 cm (Xray) below GT         0.31          0.002
  Cortical thickness ratio: 3.5 cm (DXA) and 9.5 cm (Xray) below GT   0.69          \<0.001
  Cortical thickness:4 cm (DXA) and 10.5 cm (Xray) below GT           0.29          0.003
  Cortical thickness ratio: 4 cm (DXA) and10.5 cm (Xray) below GT     0.64          \<0.001
  Cortical thickness: 0.5 cm (DXA) and 1 cm (Xray) below LT           0.26          \<0.001
  Cortical thickness ratio: 0.5 cm (DXA) and 1 cm (Xray) below LT     0.60          \<0.001
  ------------------------------------------------------------------- ------------- ---------

Discussion {#s4}
==========

In this study, we evaluated the effect of alendronate on cortical thickness of the proximal femur and compared the differences in cortical thickness between osteoporotic patients with or without alendronate therapy in BMD and X-ray.

The results suggest that alendronate treatment did not increase femoral cortex thickening within the detection limits of BMD scan or X-ray. On the other hand, a significant correlation was observed between BMD scan and x-ray especially in cortical thickness ratio: 3.5 cm (DXA) and 9.5 cm (X-ray) below GT.

There are several case reports and series that have indicated an association between long-term treatment with BPs, and the development of atypical low-energy subtrochanteric or femoral shaft fractures ([@R1]-[@R4],[@R14]). Postmenopausal osteoporosis is commonly treated with BPs especially alendronate. It is hypothesized that long term BP therapy results in oversuppression of bone turnover, leading to an accumulation of microdamage ([@R11]) and increased susceptibility of bone to fracture from low-energy injury due to changes of structural components that reduce mechanical properties under cyclic loading conditions ([@R12]). An in vitro study showed strong inhibitory effect of alendronate on human mesenchymal stem cell mediated osteogenesis by suppressing cell proliferation, osteoblast differentiation, and function ([@R16]).

Common features of atypical fractures include prodromal pain, occurrence with minimal or no trauma, a thickened diaphyseal cortex and transverse fracture pattern ([@R17]). The term cortical thickening refers to focal cortical thickening, caused by the callus reaction at the site of a fatigue fracture or to a general cortical thickness of the diaphyseal femoral shaft ([@R6]).

In a case-control study by Koeppen et al femoral cortical thickness index in 5 cm below the lesser trochanter in X-ray, were compared in 59 atypical and 218 ordinary fractures. The results did not demonstrate any significant difference between the two groups and similarly, there was no significant difference in patients with or without BP treatment or between the ipsi- and contralateral femurs in patients with an atypical fracture ([@R6]). Also, Giusti et al found a significantly higher cortical thickness index at 5 cm below the lesser trochanter in 10 patients with atypical fracture ([@R18]). Unnanuntana et al evaluated changes in cortical thickness and cortical thickness ratio at the subtrochanteric region of the proximal femur (at 3.5 and 4.0 cm under the tip of the greater trochanter) in baseline and latest hip BMD scan in 86 patients (at least 5 years alendronate treatment) and 45 controls. They observed no differences in mean changes of cortical thickness and percent changes of cortical thickness between the two groups and found that cortical thickness changed less than 1 mm in more than 90% of the patients with long-term alendronate treatment ([@R10]).

There are two points that differentiate this study from the later. First, in older studies, cortical thickness was evaluated by X-ray ([@R6],[@R18]) or BMD scan ([@R10]) only, but in this study BMD scan and X-ray were compared for evaluation of a reliable correlation of these modalities and three regions in femur were also evaluated.

We observed a low correlation of CT between DXA and X-ray (0.26-0.31) and a moderate correlation of CT ratio between DXA and X-ray (0.6-0.7). This might be due to some individual differences in femur anatomy or imaging techniques. So, future investigations are suggested to clarify whether CT ratio is a more reliable index than CT alone.

Second, former studies evaluated patients with long term alendronate consumption ([@R10]). This could cause a false idea that in present study, duration of alendronate usage was too short, however, there are some investigations reporting these fractures in younger patients or shorter duration of treatment ([@R3],[@R6]). So, our study included post-menopausal patients aged 50-70 years of old with shorter duration of BP treatment (more than one year).

There are some limitations to this study. The first and perhaps the main limitation was on our measurements from two-dimensional DXA scans and X-ray. The cortical margin of the DXA image was not well defined which might have affected the selection of measurement points.

Also, the measured points we used for each patient may represent different locations of the subtrochanteric region because of height or normal variations. However, we tried to measure three regions for better evaluation of cortical thickness. There are some reports indicating atypical fractures associated with less than 5 years alendronate therapy, so, in present study we evaluated patients with shorter duration of treatment. Although we believe further prospective studies are needed to determine the annual rate of cortical changes for longer periods. Finally, data on alendronate treatment were obtained retrospectively; therefore, we do not have accurate details on adherence and compliance to those treatments.

Apparently, alendronate treatment does not cause thickened femoral cortices at the subtrochanteric region in BMD or plain pelvic X-ray. Percent changes in cortical thickness were similar in patients with or without a history of alendronate use. BPs have a role in reducing the risk of fracture, however, concerns about their association and femoral insufficiency fractures should not preclude the use of these agents in the treatment of osteoporosis. For example, in the United States, hip fracture rates have declined by 30% coincident with bisphosphonate use ([@R19]). On the other hand, there are some reports about atypical fractures associated with other anti-osteoporotic agents such as denosumab ([@R20],[@R21]). Kim et al. found no significant association between bisphosphonate use and subtrochanteric or diaphyseal femur fractures compared with raloxifene/calcitonin ([@R22]).

Further investigations are required to determine the pathogenesis and other risk factors or predictors of atypical femoral insufficiency fractures in patients receiving long-term bisphosphonates.

Conclusion {#s5}
==========

Alendronate treatment did not appear to increase femoral CT throughout the detection limits of BMD scan or X-ray
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